1.06 AE 0.12; mean postdilation balloon diameter 3.26 AE 0.44mm; mean maximal postdilation pressure: 16.05 AE 4.24mmhg). Baseline clinical characteristics were similar between the PD and non-PD groups. The left anterior descending artery (47.8%) was the most commonly treated vessel in the study population. Lesion complexity and calcification were higher in the PD group (AHA B2/C lesion: 48.4% in PD vs 24.5% in non-PD, p < 0.001; Moderate/heavy calcification: 51.2% vs 29.6%, p<0.001). Treatment length was significantly longer in PD compared to non-PD (25.31 AE14.53 vs 20.06 AE10.13, p<0.001). Lesion preparation (percentage predilation performed and pre B:A ratio) was similar between the PD and non-PD groups. Acute lumen gain was significantly decreased in PD compared to non-PD (1.33 AE0.59 vs 1.53 AE0.63mm, p¼ 0.002). From QCA, PD resulted in a significant increase in reference vessel diameter (RVD, 0.16 AE 0.37, p< 0.001), minimal lumen diameter (MLD: 0.14 AE 0.32mm, p < 0.001) and non-significant decrease in diameter stenosis [%DS: (-)0.03 AE 12.39%, p¼ 0.976] after BRS implantation. Overall device success rates was 99.5% and allcause mortality occurred in 2.7% of the study population with no differences between the PD and non-PD groups. Other clinical outcomes are currently being adjudicated and would be available on presentation.
CONCLUSIONS In our study, while PD resulted in a marginal increase in RVD and MLD after BRS implantation, acute lumen gain was smaller in the PD group and short term procedural outcome and mortality remained similar between the 2 groups. METHODS Eighteen Absorb BVS were implanted in main coronary arteries of healthy Yucatan mini Swine. Transmission electron microscopy was performed at seven time points from 28-days to 48months. Ultrastructural changes of polymeric struts / resorption sites (RS, > 36 months) were morphologically characterized.
RESULTS Up to 12-months, struts were intact with surrounding macrophages and fibroblasts. The PDLLA polymer coating was observed as a black line of calcified material (A) as thinly separated from the strut polymer. Collagen deposition was seen along the surfaces with acellular cytoplasmic processes extending into the strut surface from the surrounding cellular area (B & C) . At 24-months the acellular processes extended deeper into the strut surface. Collagen and smooth muscle cells bordered the strut. At 30-months, some strut surfaces remained intact with surrounding dense collagen and fibroblasts (B) while other areas shows superficial polymer microfragmentation (A & C). Internally, struts appeared sparsely granular. At 36-months RS were tightly surrounded by fibrous tissue (B). Cellular and collagen-proteoglycan ingrowth subdivided RS, which show more dense granularity than at 30 months (A & C). At 42-and 48months, RS were reduced to multiple amorphous, densely granular particles subdivided and surrounded by collagen and proteoglycan rich matrix with myofibroblasts and interspersed calcified material.
CONCLUSIONS Our investigation reveals the nature of the changes seen within the polymeric struts. As polymer resorbs (30 -36 months) it shows increasing granularity (nonfibrellar glycoprotein) with eventual replacement by a proteinceous matrix with integrated collagen and myofibroblasts at 48-months. BACKGROUND The data concerning the use of bioresorbable vascular scaffolds (BVS) in coronary bifurcation lesions are limited. Given the complexity of the procedure and the potential risk of struts' damage it is imperative to evaluate the efficacy and long-term safety of BVS in such lesions. The aim of the study was to evaluate the early and longterm clinical outcomes of bifurcation stenting with BVS.
METHODS The study is a prospective, nonrandomized clinical registry of patients with coronary bifurcation lesion treated with everolimuseluting BVS. Sixty consecutive patients, with stable coronary artery disease or acute coronary syndromes were enrolled. The study excluded patients with concomitant serious illnesses, those who were unable to receive prolonged dual antiplatelet therapy or required chronic oral anticoagulation therapy. Bifurcation lesion was defined and classified according to European Bifurcation Club definition and Medina classification. The main clinical study end point was a deviceoriented target lesion failure (TLF), defined as the combination of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization.
RESULTS Sixty consecutive patients (male 71.7%, mean age 62.6AE11.2 years) were included, 18 of them had diabetes mellitus (30%) and 10 chronic kidney disease (17%). True bifurcation lesion was found in 27 patients (45%). Nine lesions (15%) comprised the left main coronary artery. On QCA the mean proximal and distal main vessel reference diameters were 3.12 AE 0.36 mm and 2.65 AE 0.43 mm respectively, whereas the mean lesion length and diameter stenosis were 12.73 AE 9.53 mm and 69.72 AE 27.33 mm. The mean side branch (SB) reference diameter was 2.34 AE 0.36 mm, SB lesion length 5.66 AE 5.27 mm, and lesion diameter stenosis 44.58AE 27.47%. A total of 71 BVS were implanted. Provisional T stenting was performed in 42 patients (70%), distal main vessel stenting in one patient, systematic T stenting in 6 (10%), and T with minimal protrusion (TAP) in 2 patients (2.2%). SB ostial stenting was performed in additional 9 patients (15%). The final mini-kissing post-dilatation was performed in 18 patients (30%). The procedural success was achieved in 98.3%. At twelve months, the rate of cardiac death was 1.7% (1 patient), target vessel myocardial infarction was 1.7% and TLR was also 1.7%, giving the TLF of (3.3%). The cumulative incidence of definite/probable scaffold thrombosis was 3.4% (2 patients). Both events happened within 10 days after procedure.
CONCLUSIONS Stenting of coronary bifurcation lesions with bioresorbable everolimus-eluting scaffolds is feasible with excellent acute performance and satisfactory early and long-term clinical outcomes. The results of our study represent a major step forward towards more complete implementation of BVS to coronary interventions. METHODS Serial OCT (after AbsorbÔ BVS implantation, 9-and 24month follow-up) was performed in 20 patients with stable angina pectoris post implantation, at 9-month and after 24 months were available in 18 patients. Dynamic changes in scaffold strut coverage and major coronary evaginations were evaluated. Coronary evaginations were defined when the maximal depth of outward bulges of the luminal contour between scaffold struts were >150 mm. Major evaginations were defined as presence of evaginations in !3 consecutive analyzed frames, with a minimal evagination depth of 10% of the nominal scaffold diameter.
RESULTS
The lesion length was 14.4 AE 3.4 mm and the scaffold length was 19.7 AE 4.2 mm. The scaffold size was 3.0 AE 0.3 mm, maximum balloon size was 3.3 AE 0.3 mm and maximum balloon pressure was 14.5 AE 2.6 atm. At baseline, 3,745 struts were analyzed. The median percentage of uncovered struts was 5.1% [25th-75th percentiles: 0.5-10.0%] after 9 months and 0.0% [0.0-0.0%] after 24 months. Completely covered scaffolds were seen in 3 patients (16.7%) after 9 months and in 17 patients (94.4%) after 24 months (p¼0.001). The median neointimal thickness increased from 9-month: 100 mm [70-120 mm] to 24-month: 115 mm [98-133 mm] (p¼0.013). The minimum lumen area decreased significantly from 5.2 mm2 [4.8-5.7 mm2] at post-implantation to 4.4 mm2 [3.7-4.8 mm2] at 9-month (p¼0.003), while no significant change was observed from 9-month to 4.5 mm2 [3.6-4.9 mm2] at 24 months, (p¼ns). Major coronary evaginations were seen in 7 patients (38.9%) at 9-month follow-up and resolved in 6 out of these 7 patients (85.7%) after 24 months.
CONCLUSIONS Almost complete scaffold strut coverage was present at 24 months without causing long-term minimum lumen area reduction. Major coronary evaginations were relatively frequent morphological findings after 9 months and mainly resolved after 24 months. METHODS REPARA is a multicenter, prospective registry, designed to evaluate the efficacy and safety of the bioresorbable coronary device Absorb (Abbott Vascular, Santa Clara, California) in daily clinical practice in more than 2400 patients undergoing elective coronary intervention in native coronary arteries in Spain and Portugal. The primary objective is a combined of MACE at 12 months, including cardiac death, myocardial infarction, TLR and stent thrombosis.
